An already big immunology market is only getting bigger: analyst by Angus Liu Thursday, April 4, 2019 Think the success of several megablockbusters such as AbbVie’s Humira means the anti-inflammation market is fully saturated? Think again.
AZ rides high on sales rebound thanks to cancer drugs, China by Angus Liu Thursday, February 14, 2019 AstraZeneca's outperforming fourth-quarter results show it is indeed back on the growth track, thanks to its cancer drugs—and once again, China.
AZ's Fasenra picks up expanded NICE backing by Angus Liu Friday, January 4, 2019 England's cost watchdog has removed a previous restriction on AZ's Fasenra, allowing it to be funded for an expanded pool of patients.
GSK execs change their tune as AZ heaps pressure on Nucala by Carly Helfand Thursday, November 8, 2018 A lot has changed in the severe asthma market lately—including the way GlaxoSmithKline is talking about its contender, Nucala.
AZ, shut out of COPD, touts long-term Fasenra asthma data by Carly Helfand Tuesday, September 18, 2018 AZ struck out in May in trying to expand Fasenra into COPD. But it does have new long-term data that could bolster the drug in its current indication.
AZ's new launches shine in Q2 as it inches toward turnaround by Carly Helfand Thursday, July 26, 2018 AstraZeneca's CEO knows he keeps saying the same thing, but once again, he had just one message for investors Thursday: Hang in there.
NICE OKs AZ’s Fasenra, but only when its GSK rival can’t be used by Carly Helfand Friday, July 20, 2018 AstraZeneca's Fasenra hasn't had an easy time challenging GlaxoSmithKline’s Nucala. And doing so just got harder close to home.
AstraZeneca's Fasenra fails second COPD trial by Carly Helfand Wednesday, May 30, 2018 AstraZeneca’s hopes for expanding severe asthma drug Fasenra into COPD are officially lost.
AstraZeneca's Fasenra ambitions take a hit with failed COPD test by Carly Helfand Friday, May 11, 2018 AZ was hoping its next-gen COPD med Fasenra could help it keep pace with GlaxoSmithKline, but the drug just failed to beat placebo in a phase 3 study.
Flopped trials dash Teva's hopes for subcutaneous Cinqair by Carly Helfand Monday, January 22, 2018 Teva was hoping to level the convenience playing field in severe asthma with a subcutaneous version of Cinqair. But those plans have hit a snag.
